Compare LZB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | CAPR |
|---|---|---|
| Founded | 1927 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1994 | 2011 |
| Metric | LZB | CAPR |
|---|---|---|
| Price | $33.92 | $30.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $42.50 | $41.38 |
| AVG Volume (30 Days) | 372.3K | ★ 921.3K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $2,349,433,000.00 | $22,270,465.00 |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $2.09 | $17,308.50 |
| P/E Ratio | $20.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.03 | $4.30 |
| 52 Week High | $44.49 | $40.37 |
| Indicator | LZB | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 66.95 |
| Support Level | $32.35 | $22.09 |
| Resistance Level | $39.84 | $40.37 |
| Average True Range (ATR) | 1.24 | 1.84 |
| MACD | -0.19 | 0.17 |
| Stochastic Oscillator | 26.54 | 92.68 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.